Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation

Launched by XIJING HOSPITAL · Apr 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a procedure called Transcatheter Aortic Valve Replacement (TAVR) to treat patients with a serious heart condition known as severe aortic valve regurgitation. This condition means that the heart's aortic valve does not close properly, causing blood to leak back into the heart. The trial aims to understand how safe and effective TAVR is for these patients. It is currently recruiting participants who are between 65 and 74 years old and have been evaluated by a specialized heart team and found to be eligible for this treatment.

To participate in this study, patients must fully understand what the trial involves and agree to take part by signing a consent form. However, patients who cannot provide this consent, those receiving TAVR for a different heart issue (aortic stenosis), or those involved in other clinical trials cannot join. Participants can expect to have their health data collected throughout the trial, which will help researchers gain important insights into the treatment's effectiveness and safety.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients diagnosed with severe aortic valve regurgitation undergo evaluation by the Heart team and are eligible for TAVR therapy.
• • 2. Patients who understand the purpose of this study, agree to participate in the trial and sign the informed consent form
• Exclusion Criteria:
• • 1. Patients who cannot provide informed consent
• • 2. Patients who are treated with TAVR for aortic stenosis
• • 3. Patients who are participating in other clinical trials